Opus Genetics (IRD) Depreciation & Amortization (CF) (2010 - 2026)
Opus Genetics (IRD) reported Depreciation & Amortization (CF) of $13000.0 for Q1 2026, little changed year-over-year from $13000.0 in Q1 2025, and little changed on a QoQ basis from $13000.0 in Q4 2025.
Opus Genetics (IRD) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $13000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53000.0 (up 130.43% YoY) and the FY2025 annual result came in at $53000.0, up 430.0% from the prior year.
- Depreciation & Amortization (CF) was little changed at $13000.0 in Q1 2026 per IRD's latest filing, from $13000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $14000.0 in Q2 2025 and bottomed at $1000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $2000.0 (2022), against an average of $6142.9.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) changed 0.0%; it then soared 233.33% in 2024.
- Tracing IRD's Depreciation & Amortization (CF) over 5 years: stood at $1000.0 in 2022, then surged by 200.0% to $3000.0 in 2023, then soared by 233.33% to $10000.0 in 2024, then advanced by 30.0% to $13000.0 in 2025, then changed by 0.0% to $13000.0 in 2026.
- Per Business Quant, the three latest IRD Depreciation & Amortization (CF) figures stand at $13000.0 (Q1 2026), $13000.0 (Q4 2025), and $13000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 8,555.00 |
| Sep 30, 2020 | 8,555.00 |
| Jun 30, 2020 | 9,203.00 |
| Jun 30, 2020 | 9,203.00 |
| Mar 31, 2020 | 9,255.00 |
| Mar 31, 2020 | 9,255.00 |
| Dec 31, 2019 | 9,532.00 |
| Dec 31, 2019 | 9,532.00 |
| Sep 30, 2019 | 9,383.00 |
| Sep 30, 2019 | 9,383.00 |
| Jun 30, 2019 | 10,544.00 |
| Jun 30, 2019 | 10,544.00 |
| Mar 31, 2019 | 11,533.00 |
| Mar 31, 2019 | 11,533.00 |
| Dec 31, 2018 | 11,007.00 |
| Dec 31, 2018 | 11,007.00 |
| Sep 30, 2018 | 10,016.00 |
| Sep 30, 2018 | 10,016.00 |
| Jun 30, 2018 | 12,588.00 |
| Jun 30, 2018 | 12,588.00 |
| Mar 31, 2018 | 14,600.00 |
| Mar 31, 2018 | 14,600.00 |
| Dec 31, 2017 | 11,395.00 |
| Dec 31, 2017 | 11,395.00 |
| Sep 30, 2017 | 11,013.00 |
| Sep 30, 2017 | 11,013.00 |
| Jun 30, 2017 | 11,023.00 |
| Jun 30, 2017 | 11,023.00 |
| Mar 31, 2017 | 8,927.00 |
| Mar 31, 2017 | 8,927.00 |
| Dec 31, 2016 | 8,793.00 |
| Dec 31, 2016 | 8,793.00 |
| Sep 30, 2016 | 9,070.00 |
| Sep 30, 2016 | 9,070.00 |
| Jun 30, 2016 | 8,892.00 |
| Jun 30, 2016 | 8,892.00 |
| Mar 31, 2016 | 6,161.00 |
| Mar 31, 2016 | 6,161.00 |
| Dec 31, 2015 | 7,556.00 |
| Dec 31, 2015 | 7,556.00 |
| Sep 30, 2015 | 7,299.00 |
| Sep 30, 2015 | 7,299.00 |
| Jun 30, 2015 | 6,478.00 |
| Jun 30, 2015 | 6,478.00 |
| Mar 31, 2015 | 6,165.00 |
| Mar 31, 2015 | 6,165.00 |
| Dec 31, 2014 | 5,907.00 |
| Dec 31, 2014 | 5,907.00 |
| Sep 30, 2014 | 3,744.00 |
| Sep 30, 2014 | 3,744.00 |
| Jun 30, 2014 | 9,630.00 |
| Jun 30, 2014 | 9,630.00 |
| Mar 31, 2014 | 9,044.00 |
| Mar 31, 2014 | 9,044.00 |
| Dec 31, 2013 | 8,937.00 |
| Dec 31, 2013 | 8,937.00 |
| Sep 30, 2013 | 9,645.00 |
| Sep 30, 2013 | 9,645.00 |
| Jun 30, 2013 | 9,235.00 |
| Jun 30, 2013 | 9,235.00 |
| Mar 31, 2013 | 9,316.00 |
| Mar 31, 2013 | 9,316.00 |
| Dec 31, 2012 | 10,223.00 |
| Dec 31, 2012 | 10,223.00 |
| Sep 30, 2012 | 10,721.00 |
| Sep 30, 2012 | 10,721.00 |
| Jun 30, 2012 | 10,721.00 |
| Jun 30, 2012 | 10,721.00 |
| Mar 31, 2012 | 10,721.00 |
| Mar 31, 2012 | 10,721.00 |
| Dec 31, 2011 | 10,166.00 |
| Dec 31, 2011 | 10,166.00 |
| Sep 30, 2011 | 10,127.00 |
| Sep 30, 2011 | 10,127.00 |
| Jun 30, 2011 | 10,650.00 |
| Jun 30, 2011 | 10,650.00 |
| Mar 31, 2011 | 14,127.00 |
| Mar 31, 2011 | 14,127.00 |
| Dec 31, 2010 | 15,816.00 |
| Dec 31, 2010 | 15,816.00 |
| Sep 30, 2010 | 11,663.00 |
| Sep 30, 2010 | 11,663.00 |
| Jun 30, 2010 | 11,633.00 |
| Jun 30, 2010 | 11,633.00 |